About this Journal Submit a Manuscript Table of Contents
Advances in Hematology
Volume 2012 (2012), Article ID 535709, 6 pages
http://dx.doi.org/10.1155/2012/535709
Review Article

JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative Neoplasms

Department of Hematology, Erasmus University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands

Received 12 September 2011; Revised 29 November 2011; Accepted 4 December 2011

Academic Editor: Mark R. Litzow

Copyright © 2012 Mar Bellido and Peter A. W. te Boekhorst. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Bennett and D. F. Stroncek, “Recent advances in the bcr-abl negative chronic myeloproliferative diseases,” Journal of Translational Medicine, vol. 4, article 41, 2006. View at Publisher · View at Google Scholar · View at PubMed
  2. A. Stoddart, M. L. Dykstra, B. K. Brown, W. Song, S. K. Pierce, and F. M. Brodsky, “Lipid rafts unite signaling cascades with clathrin to regulate BCR internalization,” Immunity, vol. 17, no. 4, pp. 451–462, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Duran, S. J. Hotté, H. Hirte et al., “Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors,” Clinical Cancer Research, vol. 13, no. 16, pp. 4849–4857, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. C. Heinrich, H. Joensuu, G. D. Demetri et al., “Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitivetyrosine kinases,” Clinical Cancer Research, vol. 14, no. 9, pp. 2717–2725, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. M. E. Weinblatt, A. Kavanaugh, M. C. Genovese, T. K. Musser, E. B. Grossbard, and D. B. Magilavy, “An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis,” The New England Journal of Medicine, vol. 363, no. 14, pp. 1303–1312, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. E. Scott, E. Hexner, A. Perl, and M. Carroll, “Targeted signal transduction therapies in myeloid malignancies,” Current Oncology Reports, vol. 12, no. 6, pp. 358–365, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. H. Grant, X. Jiang, J. Stebbing et al., “Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype,” Leukemia, vol. 24, no. 10, pp. 1817–1821, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. O. Abdel-Wahab, A. Mullally, C. Hedvat et al., “Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies,” Blood, vol. 114, no. 1, pp. 144–147, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. A. J. Mead, D. C. Linch, R. K. Hills, K. Wheatley, A. K. Burnett, and R. E. Gale, “FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia,” Blood, vol. 110, no. 4, pp. 1262–1270, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. M. Patnaik, R. A. Knudson, N. Gangat et al., “Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, ,JAK2V617F mutation analysis and clinicopathologic correlates,” European Journal of Haematology, vol. 84, no. 6, pp. 518–524, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. C. Walz, A. Chase, C. Schoch et al., “The t(8;17) (p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1,” Leukemia, vol. 19, no. 6, pp. 1005–1009, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. A. de Klein, A. G. van Kessel, G. Grosveld, et al., “A celllular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia,” Nature, vol. 300, no. 5894, pp. 765–767, 1982.
  13. C. James, V. Ugo, J. P. Le Couédic et al., “A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera,” Nature, vol. 434, no. 7037, pp. 1144–1148, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. R. L. Levine, M. Wadleigh, J. Cools et al., “Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis,” Cancer Cell, vol. 7, no. 4, pp. 387–397, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. De Vos, M. Jourdan, K. Tarte, C. Jasmin, and B. Klein, “JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells,” British Journal of Haematology, vol. 109, no. 4, pp. 823–828, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Oku, K. Takenaka, T. Kuriyama et al., “JAK2V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation: research paper,” British Journal of Haematology, vol. 150, no. 3, pp. 334–344, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. M. Boissinot, C. Cleyrat, M. Vilaine, Y. Jacques, I. Corre, and S. Hermouet, “Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F,” Oncogene, vol. 30, no. 8, pp. 990–1001, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. E. Parganas, D. Wang, D. Stravopodis et al., “JAK2 is essential for signaling through a variety of cytokine receptors,” Cell, vol. 93, no. 3, pp. 385–395, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. L. M. Scott, W. Tong, R. L. Levine et al., “JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis,” The New England Journal of Medicine, vol. 356, no. 5, pp. 459–468, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. S. T. Oh, E. F. Simonds, C. Jones et al., “Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms,” Blood, vol. 116, no. 6, pp. 988–992, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. J. A. Kennedy, F. Barabé, B. J. Patterson et al., “Expression of TEL-JAKZ in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 45, pp. 16930–16935, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. P. A. Beer, P. J. Campbell, L. M. Scott et al., “MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort,” Blood, vol. 112, no. 1, pp. 141–149, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. A. Tefferi, “Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.,” Leukemia, vol. 24, no. 6, pp. 1128–1138, 2010. View at Scopus
  24. L. Millecker, P. A. Lennon, S. Verstovsek et al., “Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations,” Cancer Genetics and Cytogenetics, vol. 197, no. 1, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. M. A. Dawson, A. J. Bannister, B. Göttgens et al., “JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin,” Nature, vol. 461, no. 7265, pp. 819–822, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. Y. Wang, W. Fiskus, D. G. Chong et al., “Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells,” Blood, vol. 114, no. 24, pp. 5024–5033, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. R. Baskin, A. Majumder, and P. P. Sayeski, “The recent medicinal chemistry development of JAK2 tyrosine kinase small molecule inhibitors,” Current Medicinal Chemistry, vol. 17, no. 36, pp. 4551–4558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Verstovsek, “Therapeutic potential of JAK2 inhibitors,” American Society of Hematology: Education Program, pp. 636–642, 2009. View at Scopus
  29. S. Verstovsek, H. Kantarjian, R. A. Mesa et al., “Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis,” The New England Journal of Medicine, vol. 363, no. 12, pp. 1117–1127, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. A. Quintás-Cardama, K. Vaddi, P. Liu et al., “Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms,” Blood, vol. 115, no. 15, pp. 3109–3117, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. T. L. Lasho, A. Tefferi, J. D. Hood, S. Verstovsek, D. G. Gilliland, and A. Pardanani, “TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients,” Leukemia, vol. 22, no. 9, pp. 1790–1792, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. G. Wernig, M. G. Kharas, R. Okabe et al., “Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera,” Cancer Cell, vol. 13, no. 4, pp. 311–320, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Tefferi, G. Barosi, R. A. Mesa et al., “International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT),” Blood, vol. 108, no. 5, pp. 1497–1503, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. Pardanani, J. R. Gotlib, C. Jamieson et al., “Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis,” Journal of Clinical Oncology, vol. 29, no. 7, pp. 789–796, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. J. W. Tyner, T. G. Bumm, J. Deininger et al., “CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms,” Blood, vol. 115, no. 25, pp. 5232–5240, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. E. O. Hexner, C. Serdikoff, M. Jan et al., “Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders,” Blood, vol. 111, no. 12, pp. 5663–5671, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. F. P. S. Santos, H. M. Kantarjian, N. Jain et al., “Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis,” Blood, vol. 115, no. 6, pp. 1131–1136, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. J. M. Goldman and J. V. Melo, “Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia,” The New England Journal of Medicine, vol. 344, no. 14, pp. 1084–1086, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. R. A. Mesa, “Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis,” IDrugs, vol. 13, no. 6, pp. 394–403, 2010. View at Scopus
  40. D. J. Barnes and J. V. Melo, “Primitive, quiescent and difficult to kill: the role of non-proliferating stem cells in chronic myeloid leukemia,” Cell Cycle, vol. 5, no. 24, pp. 2862–2866, 2006. View at Scopus
  41. A. Mullally, S. W. Lane, B. Ball et al., “Physiological JAK2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells,” Cancer Cell, vol. 17, no. 6, pp. 584–596, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. M. Lu, W. Zhang, Y. Li et al., “Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway,” Experimental Hematology, vol. 38, no. 6, pp. 472–480, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. J.-J. Kiladjian, R. A. Mesa, and R. Hoffman, “The renaissance of interferon therapy for the treatment of myeloid malignancies,” Blood, vol. 117, no. 18, pp. 4706–4715, 2011. View at Publisher · View at Google Scholar · View at PubMed
  44. T. Manshouri, Z. Estrov, A. Quintás-Cardama et al., “Bone marrow stroma-secreted cytokines protect JAK2V617F-mutated cells from the effects of a JAK2 inhibitor,” Cancer Research, vol. 71, no. 11, pp. 3831–3840, 2011. View at Publisher · View at Google Scholar · View at PubMed
  45. E. Jabbour, D. Thomas, H. Kantarjian et al., “Comparison of thalidomide and lenalidomide as therapy for myelofibrosis,” Blood, vol. 118, no. 4, pp. 899–902, 2011. View at Publisher · View at Google Scholar · View at PubMed
  46. K. H. Begna, R. A. Mesa, A. Pardanani et al., “A phase-2 trial of low-dose pomalidomide in myelofibrosis,” Leukemia, vol. 25, no. 2, pp. 301–304, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. C. Besses, A. Álvarez-Larrán, L. Martínez-Avilés et al., “Modulation of JAK2V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients,” British Journal of Haematology, vol. 152, no. 4, pp. 413–419, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus